CL2024002402A1 - Inhibidores de irak4 - Google Patents
Inhibidores de irak4Info
- Publication number
- CL2024002402A1 CL2024002402A1 CL2024002402A CL2024002402A CL2024002402A1 CL 2024002402 A1 CL2024002402 A1 CL 2024002402A1 CL 2024002402 A CL2024002402 A CL 2024002402A CL 2024002402 A CL2024002402 A CL 2024002402A CL 2024002402 A1 CL2024002402 A1 CL 2024002402A1
- Authority
- CL
- Chile
- Prior art keywords
- irak4 inhibitors
- irak4
- medicine
- consequently
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente solicitud se refiere a compuestos químicos de Fórmula (I), y sales farmacéuticamente aceptables de estos, que inhiben IRAK4 y en consecuencia tienen una posible utilidad en medicina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263267956P | 2022-02-14 | 2022-02-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024002402A1 true CL2024002402A1 (es) | 2025-01-17 |
Family
ID=85227248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024002402A CL2024002402A1 (es) | 2022-02-14 | 2024-08-12 | Inhibidores de irak4 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US12240832B2 (es) |
| EP (1) | EP4479137A1 (es) |
| JP (2) | JP7555519B2 (es) |
| KR (1) | KR20240051921A (es) |
| CN (1) | CN118591536A (es) |
| AR (1) | AR128506A1 (es) |
| AU (2) | AU2023218575B2 (es) |
| CA (1) | CA3250704A1 (es) |
| CL (1) | CL2024002402A1 (es) |
| CO (1) | CO2024012172A2 (es) |
| CR (1) | CR20240383A (es) |
| DO (1) | DOP2024000148A (es) |
| IL (1) | IL314800A (es) |
| MX (1) | MX2024009843A (es) |
| PE (1) | PE20242100A1 (es) |
| TW (1) | TW202400574A (es) |
| UY (1) | UY40145A (es) |
| WO (1) | WO2023152349A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL326433A (en) | 2023-08-11 | 2026-04-01 | Astrazeneca Ab | Crystalline irak4 inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3536685T3 (pl) | 2014-04-04 | 2022-05-16 | Pfizer Inc. | Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4 |
| WO2016174183A1 (en) | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| EP3322409A4 (en) | 2015-07-15 | 2019-07-24 | Aurigene Discovery Technologies Limited | SUBSTITUTED AZA COMPOUNDS AS IRAQ-4 INHIBITORS |
| WO2017207386A1 (de) | 2016-06-01 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Verwendung von 2-substituierten indazolen zur behandlung und prophylaxe von autoimmunerkrankungen |
| CN110785418A (zh) | 2017-06-21 | 2020-02-11 | 豪夫迈·罗氏有限公司 | 作为irak4调节剂的异二氢吲哚酮衍生物 |
| CN114585609B (zh) | 2019-06-27 | 2024-07-30 | 比奥根Ma公司 | 2h-吲唑衍生物及其在疾病治疗中的用途 |
| KR20220027196A (ko) | 2019-06-27 | 2022-03-07 | 바이오젠 엠에이 인코포레이티드 | 이미다조[1,2-a]피리디닐 유도체 및 질병의 치료에서 이것들의 용도 |
| JP7353474B2 (ja) | 2019-09-24 | 2023-09-29 | 上海美悦生物科技発展有限公司 | Irak阻害剤、その製造方法及び用途 |
| US11866405B2 (en) | 2020-12-10 | 2024-01-09 | Astrazeneca Ab | Substituted indazoles as IRAK4 inhibitors |
| EP4267576A1 (en) | 2020-12-22 | 2023-11-01 | Biogen MA Inc. | Imidazo[1,2-a]pyridine derivatives as irak4 inhibitors and their use in the treatment of disease |
| WO2022140415A1 (en) | 2020-12-22 | 2022-06-30 | Biogen Ma Inc. | 2h-indazole derivatives as irak4 inhibitors and their use in the treatment of disease |
| CA3224732A1 (en) * | 2021-07-07 | 2023-01-12 | Kevin M. Guckian | Compounds for targeting degradation of irak4 proteins |
-
2023
- 2023-02-13 WO PCT/EP2023/053416 patent/WO2023152349A1/en not_active Ceased
- 2023-02-13 MX MX2024009843A patent/MX2024009843A/es unknown
- 2023-02-13 KR KR1020247003338A patent/KR20240051921A/ko active Pending
- 2023-02-13 CR CR20240383A patent/CR20240383A/es unknown
- 2023-02-13 CA CA3250704A patent/CA3250704A1/en active Pending
- 2023-02-13 IL IL314800A patent/IL314800A/en unknown
- 2023-02-13 JP JP2024505444A patent/JP7555519B2/ja active Active
- 2023-02-13 PE PE2024001785A patent/PE20242100A1/es unknown
- 2023-02-13 CN CN202380015865.2A patent/CN118591536A/zh active Pending
- 2023-02-13 AU AU2023218575A patent/AU2023218575B2/en active Active
- 2023-02-13 EP EP23704963.0A patent/EP4479137A1/en active Pending
- 2023-02-14 UY UY0001040145A patent/UY40145A/es unknown
- 2023-02-14 AR ARP230100328A patent/AR128506A1/es unknown
- 2023-02-14 TW TW112105102A patent/TW202400574A/zh unknown
-
2024
- 2024-03-21 US US18/612,156 patent/US12240832B2/en active Active
- 2024-07-31 DO DO2024000148A patent/DOP2024000148A/es unknown
- 2024-08-12 CL CL2024002402A patent/CL2024002402A1/es unknown
- 2024-09-06 CO CONC2024/0012172A patent/CO2024012172A2/es unknown
- 2024-09-10 JP JP2024156852A patent/JP2025020096A/ja active Pending
-
2025
- 2025-02-07 US US19/047,789 patent/US20250368613A1/en active Pending
-
2026
- 2026-05-11 AU AU2026203590A patent/AU2026203590A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024009843A (es) | 2024-08-22 |
| AU2023218575A1 (en) | 2024-09-19 |
| JP2024529501A (ja) | 2024-08-06 |
| AU2026203590A1 (en) | 2026-05-28 |
| CN118591536A (zh) | 2024-09-03 |
| CO2024012172A2 (es) | 2024-09-30 |
| US20240300923A1 (en) | 2024-09-12 |
| DOP2024000148A (es) | 2024-09-15 |
| US20250368613A1 (en) | 2025-12-04 |
| PE20242100A1 (es) | 2024-10-28 |
| EP4479137A1 (en) | 2024-12-25 |
| AR128506A1 (es) | 2024-05-15 |
| UY40145A (es) | 2023-08-15 |
| KR20240051921A (ko) | 2024-04-22 |
| AU2023218575B2 (en) | 2026-06-18 |
| CA3250704A1 (en) | 2023-08-17 |
| CR20240383A (es) | 2024-11-22 |
| TW202400574A (zh) | 2024-01-01 |
| JP2025020096A (ja) | 2025-02-12 |
| US12240832B2 (en) | 2025-03-04 |
| WO2023152349A1 (en) | 2023-08-17 |
| IL314800A (en) | 2024-10-01 |
| JP7555519B2 (ja) | 2024-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39561A (es) | Inhibidores de IRAK4 | |
| CL2024002023A1 (es) | Inhibidor del inflamosoma nlrp3 y uso del mismo | |
| CO2026005655A2 (es) | Inhibidor de pan-kras y uso del mismo en medicinas | |
| CO2024003923A2 (es) | Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t | |
| NO20061432L (no) | N3 alkylerte benzimidazolederivater som MEK-inhibitorer | |
| ECSP20044709A (es) | Inhibidores de sarcómero cardíaco | |
| MA33886B1 (fr) | Dérivés substitués d'acide carbamoylméthylamino-acétique utilisés comme nouveaux inhibiteurs de nep | |
| MX2023006854A (es) | Forma cristalina de tolebrutinib, metodo de preparacion y uso de la misma. | |
| CO2024012172A2 (es) | Inhibidores de irak4 | |
| MA33364B1 (fr) | Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine | |
| UY30440A1 (es) | Nuevos compuestos | |
| MX2023014722A (es) | Forma cristalina de tolebrutinib y método de preparación y su uso. | |
| MX2012014387A (es) | Dispersiones solidas que contienen inhibidores de cinasa. | |
| PE20130396A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma | |
| AR049578A1 (es) | Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas | |
| PE20110943A1 (es) | Formulacion oral solida de alisquireno | |
| MX2024002552A (es) | Inhibidor del antigeno de membrana prostatica especifico y uso farmaceutico del mismo. | |
| MX2025007935A (es) | Nuevos inhibidores reversibles de dpp1 y usos de estos | |
| ECSP22032016A (es) | Inhibidor de irak y método de preparación para el mismo y uso del mismo | |
| UY39588A (es) | Pirazolotiazol carboxamidas y usos de estas como inhibidores de pdgfr | |
| UY37764A (es) | Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds) | |
| MX2024006975A (es) | Inhibidor de cdk9 y uso del mismo. | |
| PY2085970A (es) | Compuestos químicos | |
| CO2025002460A2 (es) | Inhibidores de topoisomerasa-1 derivados de exatecán composiciones farmacéuticas y sus usos | |
| JOP20250173A1 (ar) | مثبط بروتين أرجينين مثيل ترانسفيراز 5-مثيل ثيوأدينوزين |